All News

Innovative Cellular Therapeutics Appoints Eugene Kennedy as Chief Medical Officer

Innovative Cellular Therapeutics Appoints Eugene Kennedy as Chief Medical Officer 1366 907 Innovative Cellular Therapeutics

ROCKVILLE, Md., March 16, 2021 — Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies with a focus on solid tumors, today announced the appointment of Eugene (Gene) Kennedy, M.D. as Chief Medical Officer. Dr. Kennedy is an experienced biopharma executive with a track record of leadership in both industry and academia, and expertise in oncology, immuno-oncology, and clinical development.

“We are thrilled to announce the addition of Gene to the ICT team during this critical time for the company,” said Larry (Lei) Xiao, Ph.D., ICT’s Founder and Chief Executive Officer. “His extensive experience in overseeing clinical strategy and execution will be extremely beneficial as we advance our programs into the clinic in the United States.”

ICT has achieved compelling clinical response data in China, with an aggregate 60% Overall Response Rate (ORR) and 20% Complete Remission (CR) rate in 10 third-line patients. The seven colorectal cancer patients (57% ORR / 14% CR), and the three thyroid cancer patients (67% ORR / 33% CR), were treated with the Company’s in-house developed proprietary CoupledCAR® solid tumor CAR-T platform technology. ICT remains on track to submit U.S. Investigational New Drug (IND) applications in these two indications in 2021. 

“We are confident that our colorectal and thyroid cancer programs have been significantly de-risked. This confidence is based on the outcomes of our recent clinical proof-of-concept trials, which were conducted in patients who had exhausted all available treatment options, across four hospital sites through our Shanghai-based R&D center,” said Dr. Xiao.

Dr. Kennedy is a surgical oncologist who most recently served as Chief Medical Officer of Lumos Pharma (Lumos) and, prior to its merger with Lumos, of NewLink Genetics (NewLink). Before that, he served as NewLink’s Vice President for Clinical and Medical Affairs. In these roles, Dr. Kennedy was responsible for design, implementation, and execution of all Phase 1-3 clinical trials and for overseeing medical affairs and regulatory strategy. Dr. Kennedy has filed multiple INDs for both small molecule and biologic drug candidates.

Prior to joining NewLink, Dr. Kennedy had an academic career as Associate Professor of Surgery at Thomas Jefferson University in Philadelphia, Assistant Professor of Surgery at Louisiana State University in New Orleans, and Instructor of Surgery at the Johns Hopkins School of Medicine in Baltimore.

Dr. Kennedy received a B.A. from the University of Virginia in Charlottesville and his M.D. from the Medical College of Virginia in Richmond. He obtained his General Surgical residency and Surgical Oncology fellowship training, along with a post-doctoral fellowship in immuno-oncology, at Johns Hopkins. He also completed additional surgical training at the Royal College of Surgeons in Ireland School of Medicine Beaumont Hospital in Dublin, Ireland.

“I am extremely excited about the progress of Innovative Cellular Therapeutics’ colorectal and thyroid cancer programs towards U.S. clinical trials, and about the potential of the company’s CoupledCAR® solid tumor CAR-T platform technology in additional future indications,” said Dr. Kennedy. “The responses achieved in the company’s proof-of-concept trials in third-line colorectal and third-line thyroid cancer patients in China, and the extent to which these responses have already been confirmed in evaluations by top U.S. and Chinese independent third-party reviewing institutions, are remarkable and unprecedented. I am focused on bringing these revolutionary new therapies to cancer patients around the globe.”

About Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) is a Rockville, Maryland-based clinical stage biotechnology company focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT is in pre-Investigational New Drug (IND) discussions with the U.S. Food and Drug Administration (FDA) for its first solid tumor CAR-T programs, based on the Company’s proprietary CoupledCAR® solid tumor CAR-T platform technology. ICT has already achieved promising responses with CoupledCAR® in third-line colorectal and third-line thyroid cancer patients in ongoing clinical proof-of-concept trials being conducted across multiple hospital sites in China, coordinated through the Company’s Shanghai-based R&D center. ICT received its first U.S. Investigational New Drug (IND) application clearance for its ICTCAR014 program in late 2019. ICTCAR014 is based on ICT’s in-house developed proprietary ArmoredCAR® liquid tumor CAR-T platform technology and is a next generation CD19-targeting CAR-T therapy that expresses a dominant negative PD-1 (dnPD-1) protein to block immunosuppression by cancer cells. ICTCAR014 is being developed for patients with relapsed or refractory non-Hodgkin lymphoma (NHL), including PD-L1 positive patients. For more information, please visit www.ictbio.com.  

Investor Relations Contacts:

Morten Marott, CFO
Innovative Cellular Therapeutics
ir@ictbioinc.com

Irina Koffler
LifeSci Advisors
646-970-4681
ikoffler@lifesciadvisors.com

Media Relations Contact:

Kate L. Barrette
RooneyPartners LLC
212-223-0561
kbarrette@rooneyco.com

Innovative Cellular Therapeutics to Participate in Upcoming Investor Conferences

Innovative Cellular Therapeutics to Participate in Upcoming Investor Conferences 1704 1858 Innovative Cellular Therapeutics

ROCKVILLE, Md., Nov. 10, 2020 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for solid and liquid tumors, today announced its plans to participate in and host one-on-one meetings at three investor conferences this month.

“We appreciate the opportunity to present and discuss the recent clinical data achieved with our in-house developed, proprietary CoupledCAR® solid tumor CAR-T platform technology. We achieved a 60% Overall Response Rate (ORR) and a 20% Complete Remission (CR) rate in seven colorectal and three thyroid cancer patients. CR was achieved in both indications in ongoing human proof-of-concept trials being conducted across multiple hospital sites in China, coordinated through our R&D engine in Shanghai,” said Larry (Lei) Xiao, Ph.D., ICT’s Founder and Chief Executive Officer. “We are already in pre-IND discussions with the FDA to advance our CoupledCAR® solid tumor CAR-T therapies into the clinic in the United States in the near future.”

Investor Conference Details:

Conference: Investival Showcase Virtual 2020, partnered with Jefferies
DatesNovember 11-16, 2020
Presentation Time: Presentation is pre-recorded and accessible through the conference website below
Presenter: Morten Marott, CFO
Website Link: here

Conference: Stifel 2020 Virtual Healthcare Conference
DatesNovember 16, 2020
Presentation Time: 1:20 PM – 1:50 PM EST
Presenter: Morten Marott, CFO
Webcast Link: here

Conference: Jefferies Virtual London Healthcare Conference 2020
DatesNovember 17-19, 2020

About Innovative Cellular Therapeutics
Innovative Cellular Therapeutics (ICT) is a Rockville, Maryland-based clinical stage biotechnology company focused on the development of cellular immunotherapies for the treatment of solid and liquid tumors. ICT is in pre-Investigational New Drug (IND) discussions with the U.S. Food and Drug Administration (FDA) for its first solid tumor CAR-T programs, based on the Company’s proprietary CoupledCAR® solid tumor platform technology. ICT has already achieved promising responses with CoupledCAR® in colorectal and thyroid cancer patients in ongoing human proof-of-concept trials being conducted across multiple hospital sites in China, coordinated through its Shanghai-based R&D engine. ICT is initiating its first U.S. clinical trial with its most advanced program, ICTCAR014, after having received FDA IND clearance in late 2019. ICTCAR014 is based on ICT’s proprietary ArmoredCAR® liquid tumor platform technology and is a next generation CD19-targeting CAR-T therapy that expresses a dominant negative PD-1 (dnPD-1) protein to block immunosuppression by cancer cells. ICTCAR014 is being developed for patients with relapsed or refractory non-Hodgkin lymphoma (NHL), including PD-L1 positive patients. For more information, please visit www.ictbio.com.


Investor Relations Contacts:

Morten Marott, CFO
Innovative Cellular Therapeutics
ir@ictbioinc.com

Irina Koffler
LifeSci Advisors
646-970-4681
ikoffler@lifesciadvisors.com

Media Relations Contact:

Kate L. Barrette
RooneyPartners LLC
212-223-0561
kbarrette@rooneyco.com

Innovative Cellular Therapeutics to Present CoupledCAR® Solid Tumor CAR-T Clinical Data at Upcoming Scientific Meetings

Innovative Cellular Therapeutics to Present CoupledCAR® Solid Tumor CAR-T Clinical Data at Upcoming Scientific Meetings 671 768 Innovative Cellular Therapeutics

ROCKVILLE, Md., Nov. 10, 2020 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for solid and liquid tumors, today announced its plans to present CoupledCAR® solid tumor CAR-T clinical data at two key oncology conferences.

ICT will make data presentations at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) and at the American Society of Hematology (ASH) 62nd ASH Annual Meeting and Exposition (ASH 2020) conferences. The data describe two heavily pre-treated patient groups with colorectal cancer and thyroid cancer, respectively. The group of seven colorectal cancer patients was treated with anti-GCC (guanylate cyclase 2C) CoupledCAR® CAR-T cells, while the group of three thyroid cancer patients was treated with anti-TSHR (thyroid stimulating hormone receptor) CoupledCAR® CAR-T cells. In both groups, the CoupledCAR® CAR-T cells showed rapid and significant expansion in vivo as well as infiltration into the tumor tissue sites, demonstrating enhanced tumor killing and shrinkage. 71.4% (5/7) Overall Response Rate (ORR) and 14.3% (1/7) Complete Remission (CR) rate was achieved in the colorectal cancer group. 66.7% (2/3) ORR and 33.3% (1/3) CR was achieved in the thyroid cancer group.

“CoupledCAR® is ICT’s novel, in-house developed, proprietary CAR-T platform technology designed to overcome the challenges observed with conventional CAR-T therapies in treating solid tumors. CoupledCAR® significantly improves the expansion of CAR-T cells in vivo and enhances the CAR-T cells’ migration ability and resistance to immunosuppression in the tumor microenvironment. This allows the CoupledCAR® CAR-T cells to infiltrate tumor tissue sites and increase anti-tumor activities,” said Larry (Lei) Xiao, Ph.D., ICT’s Founder and Chief Executive Officer. “We are excited to share the strong human proof-of-concept efficacy results achieved with CoupledCAR® across multiple hospital sites in China, coordinated through our R&D engine in Shanghai, and have initiated pre-IND discussions with the FDA to advance our CoupledCAR® solid tumor CAR-T therapies into the clinic in the United States in the near future.”

SITC 2020 Presentations:

Session Date/Time: November 11-14, 2020, 9:00 AM – 5:00 PM EST
Session Title/Location: Virtual Poster Hall
Abstract Title: Novel CoupledCARTM Technology for Treating Colorectal Cancer
Abstract Number: 701

Session Date/Time: November 11-14, 2020, 9:00 AM – 5:00 PM EST
Session Title/Location: Virtual Poster Hall
Abstract Title: CoupledCARTM Technology for Treating Thyroid Cancer
Abstract Number: 700

ASH 2020 Presentations: 

Session Date/Time: Sunday, December 6, 2020, 2:00 PM – 3:30 PM PST 
Session Title/Location: 801. Gene Editing, Therapy and Transfer I
Abstract Title: Novel CoupledCARTM Technology for Treating Colorectal Cancer
Oral Presentation Time: 3:00 PM PST
Publication Number: 501 – link here

Session Date/Time: Saturday, December 5, 2020, 7:00 AM – 3:30 PM PST
Session Title/Location: 801. Gene Editing, Therapy and Transfer: Poster I
Abstract Title: CoupledCARTM Technology for Treating Thyroid Cancer
Publication Number: 1541 – link here

About Innovative Cellular Therapeutics
Innovative Cellular Therapeutics (ICT) is a Rockville, Maryland-based clinical stage biotechnology company focused on the development of cellular immunotherapies for the treatment of solid and liquid tumors. ICT is in pre-Investigational New Drug (IND) discussions with the U.S. Food and Drug Administration (FDA) for its first solid tumor CAR-T programs, based on the Company’s proprietary CoupledCAR® solid tumor platform technology. ICT has already achieved promising responses with CoupledCAR® in colorectal and thyroid cancer patients in ongoing human proof-of-concept trials being conducted across multiple hospital sites in China, coordinated through its Shanghai-based R&D engine. ICT is initiating its first U.S. clinical trial with its most advanced program, ICTCAR014, after having received FDA IND clearance in late 2019. ICTCAR014 is based on ICT’s proprietary ArmoredCAR® liquid tumor platform technology and is a next generation CD19-targeting CAR-T therapy that expresses a dominant negative PD-1 (dnPD-1) protein to block immunosuppression by cancer cells. ICTCAR014 is being developed for patients with relapsed or refractory non-Hodgkin lymphoma (NHL), including PD-L1 positive patients. For more information, please visit www.ictbio.com.


Investor Relations Contacts:

Morten Marott, CFO
Innovative Cellular Therapeutics
ir@ictbioinc.com

Irina Koffler
LifeSci Advisors
646-970-4681
ikoffler@lifesciadvisors.com

Media Relations Contact:

Kate L. Barrette
RooneyPartners LLC
212-223-0561
kbarrette@rooneyco.com

Innovative Cellular Therapeutics to Present New Clinical Data with CoupledCAR® CAR-T in Colon Cancer at the LifeSci Partners Private Company Virtual Summer Symposium on August 5, 2020

Innovative Cellular Therapeutics to Present New Clinical Data with CoupledCAR® CAR-T in Colon Cancer at the LifeSci Partners Private Company Virtual Summer Symposium on August 5, 2020 470 631 Innovative Cellular Therapeutics

ROCKVILLE, Md., July 28, 2020 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for solid and liquid tumors, today announced that it will present new clinical data at the LifeSci Partners Private Company Virtual Summer Symposium on August 5, 2020.

“We have seen a 71% Overall Response Rate with 14% Complete Response in seven metastatic colon cancer patients treated in proof-of-concept trials in China with CoupledCAR®, ICT’s novel, in-house developed, proprietary CAR-T platform technology for solid tumors,” said Larry (Lei) Xiao, Ph.D., ICT’s Founder and Chief Executive Officer. “We are excited to present details on our recent advancements, as we move towards U.S. IND filings for our CoupledCAR® solid tumor CAR-T therapies,” he added.

LifeSci Partners Summer Symposium Presentation Details

Session Date: Wednesday August 5, 2020 
Presentation Time: 7:30 AM – 7:55 AM EDT
Presenter:  Victor Lu, PhD, SVP, Head of Regulatory Affairs, Innovative Cellular Therapeutics 
Webcast Registration Information: https://lifesci.events/SummerSymposium 

About Innovative Cellular Therapeutics
Innovative Cellular Therapeutics (ICT) is a Rockville, Maryland-based clinical stage biotechnology company focused on the development of cellular immunotherapies for the treatment of solid and liquid tumors. ICT is in pre-Investigational New Drug (IND) discussions with the U.S. Food and Drug Administration (FDA) for its first solid tumor CAR-T programs, based on the Company’s proprietary CoupledCAR® solid tumor platform technology. ICT has already achieved promising responses with CoupledCAR® in colon and thyroid cancer patients in human proof-of-concept trials through its Shanghai-based R&D platform. ICT is initiating its first U.S. clinical trial with its most advanced program, ICTCAR014, after having received FDA IND clearance in late 2019. ICTCAR014 is based on ICT’s proprietary ArmoredCAR® liquid tumor platform technology and is a next generation CD19-targeting CAR-T therapy that expresses a dominant negative PD-1 (dnPD-1) protein to block immunosuppression by cancer cells. ICTCAR014 is being developed for patients with relapsed or refractory non-Hodgkin lymphoma (NHL), including PD-L1 positive patients. For more information, please visit www.ictbio.com


Investor Relations Contacts:

Morten Marott, CFO
Innovative Cellular Therapeutics
ir@ictbioinc.com

Bob Yedid
LifeSci Advisors
646-597-6989
bob@lifesciadvisors.com

Irina Koffler
LifeSci Advisors
646-970-4681
ikoffler@lifesciadvisors.com

Media Relations Contact:

Kate L. Barrette
RooneyPartners LLC
212-223-0561
kbarrette@rooneyco.com

Innovative Cellular Therapeutics Announces Details of Two Abstracts on its Novel CoupledCAR® Solid Tumor CAR-T Technology to be Presented Orally at the 23rd American Society of Gene & Cell Therapy Meeting

Innovative Cellular Therapeutics Announces Details of Two Abstracts on its Novel CoupledCAR® Solid Tumor CAR-T Technology to be Presented Orally at the 23rd American Society of Gene & Cell Therapy Meeting 1719 1732 Innovative Cellular Therapeutics

ROCKVILLE, Md., April 29, 2020 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for solid and liquid tumors, today announced details of two abstracts on its novel CoupledCAR® solid tumor CAR-T technology for treating colorectal and thyroid cancers. The abstracts have been selected for oral presentation on May 15, 2020, at the 23rd American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, which will be conducted virtually.

“CoupledCAR® is ICT’s novel, in-house developed, proprietary CAR-T platform technology designed to overcome the challenges observed with conventional CAR-T therapies in treating solid tumors. CoupledCAR® significantly improves the expansion of CAR-T cells in vivo and enhances the CAR-T cells’ migration ability and resistance to immunosuppression in the tumor microenvironment. This allows the CoupledCAR® CAR-T cells to infiltrate tumor tissue sites and increase anti-tumor activities,” said Larry (Lei) Xiao, Ph.D., ICT’s Founder and Chief Executive Officer. “We are excited to share the strong human proof-of-concept efficacy results achieved with CoupledCAR® in China and have initiated pre-IND discussions with the FDA to advance our CoupledCAR® solid tumor CAR-T therapies into the clinic in the United States in the near future.”

ICT will present the two abstracts back-to-back in a virtual presentation on Friday, May 15, 2020, at 9:30 AM EDT, during the Clinical Trials Spotlight Symposium. The abstracts describe two heavily pre-treated patient cohorts with colorectal cancer and thyroid cancer, respectively, that achieved near Complete Remission (nCR) or Partial Remission (PR) after treatment with CoupledCAR®, and may be found here.

Novel CoupledCAR® Technology for Treating Colorectal Cancer

Session Date/Time: Friday May 15, 2020 8:00 AM – 9:45 AM EDT
Session Title/Location: Clinical Trials Spotlight Symposium, Room 310
Presentation Time: 9:30 AM – 9:45 AM EDT
Presenter:  Larry (Lei) Xiao, PhD, Innovative Cellular Therapeutics 
Abstract Number: 1304

CoupledCAR® Technology for Treating Thyroid Cancer

Session Date/Time: Friday May 15, 2020 8:00 AM – 9:45 AM EDT
Session Title/Location: Clinical Trials Spotlight Symposium, Room 310
Presentation Time: 9:30 AM – 9:45 AM EDT
Presenter: Larry (Lei) Xiao, PhD, Innovative Cellular Therapeutics
Abstract Number: 1303

About Innovative Cellular Therapeutics
Innovative Cellular Therapeutics (ICT) is a Rockville, Maryland-based clinical stage biotechnology company focused on the development of cellular immunotherapies for the treatment of solid and liquid tumors. ICT is in pre-Investigational New Drug (IND) discussions with the U.S. Food and Drug Administration (FDA) for its first solid tumor CAR-T programs, based on the Company’s proprietary CoupledCAR® solid tumor platform technology. ICT has already achieved promising responses with CoupledCAR® in thyroid, colon, and prostate cancer patients in human proof-of-concept trials through its Shanghai-based R&D platform. ICT is initiating its first U.S. clinical trial with its most advanced program, ICTCAR014, after having received FDA IND clearance in late 2019. ICTCAR014 is based on ICT’s proprietary ArmoredCAR® liquid tumor platform technology and is a next generation CD19-targeting CAR-T therapy that expresses a dominant negative PD-1 (dnPD-1) protein to block immunosuppression by cancer cells. ICTCAR014 is being developed for patients with relapsed or refractory non-Hodgkin lymphoma (NHL), including PD-L1 positive patients. For more information, please visit www.ictbio.com.  


Investor Relations Contacts:

Morten Marott, CFO
Innovative Cellular Therapeutics
ir@ictbioinc.com

Bob Yedid
LifeSci Advisors
646-597-6989
bob@lifesciadvisors.com

Irina Koffler
LifeSci Advisors
646-970-4681
ikoffler@lifesciadvisors.com

Media Relations Contact:

Kate L. Barrette
RooneyPartners LLC
212-223-0561
kbarrette@rooneyco.com

Innovative Cellular Therapeutics Announces Acceptance of Abstract on its Novel CoupledCAR® Technology for Treating Colorectal Cancer for Oral Presentation at the 23rd American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Innovative Cellular Therapeutics Announces Acceptance of Abstract on its Novel CoupledCAR® Technology for Treating Colorectal Cancer for Oral Presentation at the 23rd American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 1300 1625 Innovative Cellular Therapeutics

ROCKVILLE, Md., April 14, 2020 — Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for solid and liquid tumors, today announced acceptance of its abstract titled Novel CoupledCAR® Technology for Treating Colorectal Cancer. The abstract will be presented orally at the 23rd American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, which will be conducted virtually, May 12-15, 2020.

“CoupledCAR® is ICT’s novel, in-house developed, proprietary CAR-T platform technology for the treatment of solid tumors. We have already achieved promising responses in several indications with CoupledCAR® in human proof-of-concept trials in China. We have also initiated pre-IND discussions with the FDA on taking several of our CoupledCAR® therapies into clinical trials in the United States,” said Larry (Lei) Xiao, Ph.D., ICT’s Founder and Chief Executive Officer. “We are excited for the opportunity to share our human data and strong efficacy results from our CoupledCAR® colorectal tumor program with the scientific community at ASGCT in May.”

The oral presentation of ICT’s abstract will be conducted virtually on Friday, May 15, 2020, at 9:30 AM EDT during the Clinical Trials Spotlight Symposium. Additional details are provided below.

Novel CoupledCAR® Technology for Treating Colorectal Cancer

Session Date/Time: Friday May 15, 2020, 8:00 AM – 9:45 AM EDT
Session Title: Clinical Trials Spotlight Symposium
Presentation Time: 9:30 AM – 9:45 AM EDT

About Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) is a Rockville, Maryland-based clinical stage biotechnology company focused on the development of cellular immunotherapies for the treatment of solid and liquid tumors. ICT is in pre-Investigational New Drug (IND) discussions with the U.S. Food and Drug Administration (FDA) for its first solid tumor CAR-T programs, based on the Company’s proprietary CoupledCAR® solid tumor platform technology. ICT has already achieved promising responses with CoupledCAR® in thyroid, colon, and prostate cancer patients in human proof-of-concept trials through its Shanghai-based R&D platform. ICT is initiating its first U.S. clinical trial with its most advanced program, ICTCAR014, after having received FDA IND clearance in late 2019. ICTCAR014 is based on ICT’s proprietary ArmoredCAR® liquid tumor platform technology and is a next generation CD19-targeting CAR-T therapy that expresses a dominant negative PD-1 (dnPD-1) protein to block immunosuppression by cancer cells. ICTCAR014 is being developed for patients with relapsed or refractory non-Hodgkin lymphoma (NHL), including PD-L1 positive patients. For more information, please visit www.ictbio.com


Investor Relations Contacts:

Morten Marott, CFO
Innovative Cellular Therapeutics
ir@ictbioinc.com

Bob Yedid
LifeSci Advisors
646-597-6989
bob@lifesciadvisors.com

Irina Koffler
LifeSci Advisors
646-970-4681
ikoffler@lifesciadvisors.com

Media Relations Contact:

Kate L. Barrette
RooneyPartners LLC
212-223-0561
kbarrette@rooneyco.com

Maryland Tech Council Announces Nomination of Innovative Cellular Therapeutics as “Emerging Life Sciences Company of the Year” Finalist

Maryland Tech Council Announces Nomination of Innovative Cellular Therapeutics as “Emerging Life Sciences Company of the Year” Finalist 1745 1664 Innovative Cellular Therapeutics

ROCKVILLE, Md., March 10, 2020 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for solid and liquid tumors, announced today that it has been nominated as a finalist for “Emerging Life Sciences Company of the Year,” by Maryland Tech Council (MTC). The winner of the award will be revealed at MTC’s annual Industry Awards Celebration on May 13, 2020.

MTC is the largest technology trade group serving the advanced technology and biotechnology communities of Maryland. Its mission is to advocate for the interests of the technology community, further the role of technology in the Maryland economy, and nurture an environment where technology companies can collaborate, grow and succeed.

“We are honored to be nominated for the Emerging Life Sciences Company of the Year award by Maryland Tech Council,” said Larry (Lei) Xiao, Ph.D., ICT’s Founder and Chief Executive Officer. “After establishing our U.S. business in 2018, we moved our global headquarters to Rockville in early 2019 to further concentrate our focus on the U.S. market and to leverage the strong life sciences talent pool in Maryland as we expand our operations and hiring in the area.”

Dr. Xiao noted that ICT has already made significant progress since moving to Maryland, including hiring most of ICT’s senior executives and obtaining FDA IND clearance for the Company’s ArmoredCAR® ICTCAR014 CAR-T program, which is now moving into a U.S. Phase 1 clinical trial in relapsed or refractory NHL, including for PD-L1 positive patients. ICT has also initiated pre-IND discussions with the FDA for its first CoupledCARTM based solid tumor CAR-T programs.

“We appreciate the support and recognition from Maryland Tech Council and the local life sciences community during this exciting time for our company,” Dr. Xiao added.

About Innovative Cellular Therapeutics
Innovative Cellular Therapeutics (ICT) is a Rockville, Maryland based clinical stage biotechnology company focused on the development of cellular immunotherapies for the treatment of solid and liquid tumors. ICT is in pre-IND discussions with the U.S. Food and Drug Administration (FDA) for its first solid tumor CAR-T programs, based on the Company’s proprietary CoupledCARTM solid tumor platform technology. ICT has already achieved promising responses with CoupledCARTM in thyroid, colon, and prostate cancer patients in human proof-of-concept trials through its Shanghai based R&D platform. ICT is initiating its first U.S. clinical trial with its most advanced program, ICTCAR014, after having received U.S. FDA Investigational New Drug (IND) application clearance in late 2019. ICTCAR014 is based on ICT’s proprietary ArmoredCAR® liquid tumor platform technology and is a next generation CD19-targeting CAR-T therapy that expresses a dominant negative PD-1 (dnPD-1) protein to block immunosuppression by cancer cells. ICTCAR014 is being developed for patients with relapsed or refractory non-Hodgkin lymphoma (NHL), including PD-L1 positive patients. For more information, please visit www.ictbio.com.  


Investor Relations Contacts:

Morten Marott, CFO
Innovative Cellular Therapeutics
ir@ictbioinc.com

Irina Koffler
LifeSci Advisors
646-970-4681
ikoffler@lifesciadvisors.com

Media Relations Contacts:

Kate L. Barrette
RooneyPartners LLC
212-223-0561
kbarrette@rooneyco.com

Innovative Cellular Therapeutics Appoints Cell and Gene Therapy Manufacturing Expert Christopher Ballas, Ph.D., as SVP of Manufacturing

Innovative Cellular Therapeutics Appoints Cell and Gene Therapy Manufacturing Expert Christopher Ballas, Ph.D., as SVP of Manufacturing 1366 911 Innovative Cellular Therapeutics

ROCKVILLE, Md., January 07, 2020 — Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for liquid and solid tumors, today announced the appointment of Christopher Ballas, Ph.D., as Senior Vice President of Manufacturing. Dr. Ballas previously served in senior manufacturing roles at Rocket Pharmaceuticals and WuXi AppTec, with a focus on gene and cell-based therapies. 

“Our need for quality vector and cell production is growing as we advance our liquid and solid tumor CAR-T programs into the clinic in the United States. We intend to assume full control of our key manufacturing processes,” said Larry (Lei) Xiao, Ph.D., ICT’s Founder and Chief Executive Officer. “Chris is a valued addition to the ICT management team, as he will lead our manufacturing efforts and the expansion of our related infrastructure,” Dr. Xiao added.

Dr. Ballas brings more than 20 years’ experience of working on cell and gene therapies. Most recently, he served as Vice President of Manufacturing for Rocket Pharmaceuticals, a leading publicly traded U.S. gene therapy company. Previously, he served as Senior Director of Process Development and Commercialization for WuXi AppTec, where he was responsible for manufacturing operations and program management for gene therapy clients. Dr. Ballas oversaw key programs including CAR-T, TIL, and classic CD34+ stem cell gene therapy. 

Prior to WuXi AppTec, Dr. Ballas ran autologous cell therapy clinical trials for Cook Medical. Dr. Ballas also held several roles at the Indiana University School of Medicine, where he developed the initial, scalable, clinical production capabilities for lentiviral vectors at the IU Vector Production Facility. As a faculty member, Dr. Ballas developed his own research programs targeting stem cells for gene therapy, which resulted in the collaborative development of an ultra-high throughput microinjection device with colleagues at the University of California Riverside (US9885059). In the past, Dr. Ballas served as an expert consultant to numerous companies on gene therapy and the production and use of viral vectors for gene therapies with contributions to Chemistry, Manufacturing, and Control (CMC), regulatory filings, and regulatory meetings.

Dr. Ballas has a Ph.D. in Cellular and Molecular Pathology from the Vanderbilt University School of Medicine and was a Children’s Brittle Bone Foundation fellow during his post-doctoral fellowship at Case Western Reserve University School of Medicine.

Dr. Ballas said, “I have a passion for solving the practical challenges associated with producing and using viral vectors to deliver genes and create differentiated therapies. ICT’s CAR-T platform is unique and compelling, and I look forward to leveraging my experience to optimize and expand our manufacturing capability to produce world-class products with the potential to transform cancer immunotherapy.”

About Innovative Cellular Therapeutics
Innovative Cellular Therapeutics (ICT) is a clinical stage biotechnology company focused on the development of cellular immunotherapies for the treatment of liquid and solid tumors. ICT has achieved promising preclinical and clinical results in late-stage leukemia and lymphoma with its next generation CAR-T constructs. ICT’s lead candidate in the United States, ICTCAR014, is a next generation CD19-targeting armored CAR-T cell therapy that expresses a dominant negative PD-1 (dnPD-1) protein to block immunosuppression by cancer cells. ICTCAR014 is being developed for patients with relapsed or refractory non-Hodgkin lymphoma (NHL), including PD-L1 positive patients. In solid tumor, ICT has compelling human data from IRB-approved proof-of-concept trials in China demonstrating the viability of its proprietary “CoupledCAR” technology platform. For more information, please visit www.ictbio.com.


Investor Relations Contacts:

Morten Marott, CFO
Innovative Cellular Therapeutics
ir@ictbioinc.com

Bob Yedid
LifeSci Advisors
646-597-6989
ir@ictbioinc.com

Media Relations Contacts:

Kate L. Barrette
RooneyPartners LLC
212-223-0561
kbarrette@rooneyco.com

Innovative Cellular Therapeutics Secures Equity Financing to Advance its Next Generation Liquid and Solid Tumor CAR-T Programs

Innovative Cellular Therapeutics Secures Equity Financing to Advance its Next Generation Liquid and Solid Tumor CAR-T Programs 1366 907 Innovative Cellular Therapeutics

ROCKVILLE, Md., Dec. 17, 2019 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for liquid and solid tumors, today announced that it has closed a U.S. dollar Series B+ equity financing for an undisclosed amount. The lead investor, LH Ventures, is a prominent venture capital firm targeting disruptive technologies in the healthcare sector and other innovations. Proceeds from the capital raise will be used to advance ICTCAR014 – ICT’s next generation CD19-targeting armored CAR-T cell therapy that expresses a dominant negative PD-1 protein to block immunosuppression by cancer cells – into a U.S. clinical trial in the first part of 2020, and to further develop ICT’s “CoupledCAR” CAR-T cell therapy platform in solid tumors.

“We are deeply impressed by the ICT team, their innovation capabilities and the response of the initial patients to the Company’s next generation armored dominant negative PD-1 CAR-T cell therapy and CoupledCAR technologies,” said Xin Xie, Ph.D., Partner at LH Ventures. “We believe ICT’s platform technologies will create significant breakthroughs in the fight against both liquid and solid tumors.”

“We are excited to have LH Ventures support the expansion of our global activities and help us advance the clinical development of our next generation CAR-T technologies for liquid and solid tumors in the United States,” said Larry (Lei) Xiao, Ph.D., ICT’s Founder and Chief Executive Officer. “They are joined by a group of other renowned, international investors who also believe in the viability of our platform technologies.”

About LH Ventures
LH Ventures is a prominent venture capital firm targeting early stage opportunities of innovation and disruptive technologies. It boasts an investment team consisting of entrepreneurs, scientists, doctors, and capital market experts. LH Ventures identifies teams and companies which have significant value potential and helps them grow into industry leaders.

About ICTCAR014
The U.S. Food and Drug Administration (FDA) has cleared ICT’s Investigational New Drug (IND) application for ICTCAR014, a next generation CD19-targeting CAR-T cell therapy that expresses a dominant negative PD-1 protein to block immunosuppression by cancer cells. ICT is moving ICTCAR014 into a U.S. clinical trial. ICTCAR014, referred to as an “armored” CAR-T cell therapy, has already shown encouraging results in proof-of-concept human trials in China. As highlighted in ICT’s presentation at the November 2019 Society for the Immunotherapy of Cancer (SITC) meeting, ICTCAR014 demonstrated a 92.3% objective response rate (53.8% complete remission; 38.5% partial remission) in 13 initial patients with relapsed or refractory non-Hodgkin lymphoma. Significant tumor shrinkage and limited toxicity were observed.

About Innovative Cellular Therapeutics
Innovative Cellular Therapeutics (ICT) is a clinical stage biotechnology company focused on the development of cellular immunotherapies for the treatment of liquid and solid tumors. ICT has achieved promising preclinical and clinical results in late-stage leukemia and lymphoma with its next generation CAR-T constructs. ICT’s lead candidate in the United States, ICTCAR014, is a next generation CD19-targeting armored CAR-T cell therapy that expresses a dominant negative PD-1 (dnPD-1) protein to block immunosuppression by cancer cells. ICTCAR014 is being developed for patients with relapsed or refractory non-Hodgkin lymphoma (NHL), including PD-L1 positive patients. In solid tumor, ICT has compelling human data from IRB-approved proof-of-concept trials in China demonstrating the viability of its proprietary “CoupledCAR” technology platform. For more information, please visit www.ictbio.com.


Investor Relations Contacts:

Morten Marott, CFO
Innovative Cellular Therapeutics
ir@ictbioinc.com

Bob Yedid
LifeSci Advisors
646-597-6989
ir@ictbioinc.com

Media Relations Contacts:

Kate L. Barrette
RooneyPartners LLC
212-223-0561
kbarrette@rooneyco.com

Innovative Cellular Therapeutics Strengthens Executive Leadership Team with Appointment of Morten Marott as Chief Financial Officer

Innovative Cellular Therapeutics Strengthens Executive Leadership Team with Appointment of Morten Marott as Chief Financial Officer 1366 911 Innovative Cellular Therapeutics

ROCKVILLE, Md., December 5, 2019 — Innovative Cellular Therapeutics (ICT), a biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for liquid and solid tumors, today announced the appointment of Morten Marott, who joined ICT as Chief Financial Officer in July 2019. Mr. Marott was formerly Chief Financial Officer of publicly traded Veloxis Pharmaceuticals A/S and has extensive M&A and capital markets experience from Wall Street.

“Morten has already been invaluable to our company in terms of setting us up for success, as we expand our U.S. activities,” said Larry (Lei) Xiao, Ph.D., ICT’s Chairman and Chief Executive Officer. “We look forward to Morten’s continued guidance and strategic planning expertise as we seek to expand our clinical stage pipeline of next generation CAR-T cell therapies to transform cancer treatments worldwide. We are already off to a strong start in the United States with the recent clearance by the U.S. Food and Drug Administration (FDA) of our Investigational New Drug (IND) application for ICTCAR014 in patients with relapsed or refractory non-Hodgkin lymphoma (NHL), including patients whose tumors are PD-L1 positive.”

Before joining ICT, Mr. Marott was Chief Financial Officer of Veloxis Pharmaceuticals A/S, a publicly traded biopharmaceutical company located in Cary, North Carolina, where he drove the corporate strategy, business development and global investor relations efforts. Previously, Mr. Marott was a senior investment banker in the Healthcare Investment Banking Group at Deutsche Bank in New York. Prior to this, he was with the Healthcare Investment Banking Groups of RBC Capital Markets and Citigroup. He has more than a decade of Wall Street experience in M&A, healthcare investment banking and equity research with a primary focus on the U.S. biopharmaceutical industry.

Mr. Marott holds an MBA in finance and accounting from the Wharton School of the University of Pennsylvania, a Business Administration degree from Copenhagen Business School, and Bachelor and Master of Law degrees (JD) from the University of Copenhagen.

“ICT’s innovative CAR-T technology platform, strong in-house R&D team and manufacturing capability are the core of the Company’s rapid global development strategy,” Mr. Marott said. “These are key differentiating factors in the CAR-T space. I look forward to ensuring that ICT reaches meaningful value inflection points and validates its clinical programs.”

About ICTCAR014

The U.S. Food and Drug Administration (FDA) has cleared ICT’s Investigational New Drug (IND) application for ICTCAR014, a next generation CD19-targeting CAR-T cell therapy that expresses a dominant negative PD-1 protein to block immunosuppression by cancer cells. ICT is moving ICTCAR014 into a U.S. clinical trial. ICTCAR014, referred to as an “armored” CAR-T cell therapy,

has already shown encouraging results in proof-of-concept human trials in China. As highlighted in ICT’s presentation at the November 2019 Society for the Immunotherapy of Cancer (SITC) meeting, ICTCAR014 demonstrated a 92.3% objective response rate (53.8% complete remission; 38.5% partial remission) in 13 initial patients with relapsed or refractory non-Hodgkin lymphoma. Significant tumor shrinkage and limited toxicity were observed.

About Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) is a clinical stage biotechnology company focused on the development of cellular immunotherapies for the treatment of liquid and solid tumors. ICT has achieved promising preclinical and clinical results in late-stage leukemia and lymphoma with its next generation CAR-T constructs. ICT’s lead candidate in the U.S., ICTCAR014, is a next generation CD19-targeting CAR-T cell therapy that expresses a dominant negative PD-1 (dnPD-1) protein to block immunosuppression by cancer cells. ICTCAR014 is being developed for patients with relapsed or refractory non-Hodgkin lymphoma (NHL), including PD-L1 positive patients. ICT’s lead candidate in China, ICTCAR003, is a CD19-targeting CAR-T cell therapy for the treatment of B-cell acute lymphoblastic leukemia. The Company also has a broad pipeline of CAR-T candidates targeting solid tumors. For more information, please visit www.ictbio.com.


Investor Relations Contacts:

Morten Marott, CFO
Innovative Cellular Therapeutics
ir@ictbioinc.com

Bob Yedid
LifeSci Advisors
646-597-6989
ir@ictbioinc.com

Media Relations Contacts:

Kate L. Barrette
RooneyPartners LLC
212-223-0561
kbarrette@rooneyco.com

  • 1
  • 2